AZN vs. SHEL: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AZN and SHEL, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Both AZN and SHEL are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.
| Symbol | AZN | SHEL |
|---|---|---|
| Company Name | AstraZeneca PLC | Shell plc |
| Country | United Kingdom | United Kingdom |
| GICS Sector | Health Care | Energy |
| GICS Industry | Pharmaceuticals | Oil, Gas & Consumable Fuels |
| Market Capitalization | 249.69 billion USD | 209.92 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | May 12, 1993 | March 12, 1984 |
| Security Type | ADR | ADR |
Historical Performance
This chart compares the performance of AZN and SHEL by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AZN | SHEL |
|---|---|---|
| 5-Day Price Return | 2.95% | 1.45% |
| 13-Week Price Return | 12.30% | 7.61% |
| 26-Week Price Return | 0.63% | -0.30% |
| 52-Week Price Return | -9.49% | -1.55% |
| Month-to-Date Return | 4.04% | -1.66% |
| Year-to-Date Return | 12.55% | 7.67% |
| 10-Day Avg. Volume | 1.07M | 4.94M |
| 3-Month Avg. Volume | 1.56M | 5.97M |
| 3-Month Volatility | 22.19% | 18.39% |
| Beta | 0.98 | 1.19 |
Profitability
Return on Equity (TTM)
AZN
19.84%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
AZN’s Return on Equity of 19.84% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
SHEL
7.40%
Oil, Gas & Consumable Fuels Industry
- Max
- 35.51%
- Q3
- 17.86%
- Median
- 10.69%
- Q1
- 5.71%
- Min
- -8.98%
SHEL’s Return on Equity of 7.40% is on par with the norm for the Oil, Gas & Consumable Fuels industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
AZN
14.68%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
AZN’s Net Profit Margin of 14.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
SHEL
5.00%
Oil, Gas & Consumable Fuels Industry
- Max
- 44.03%
- Q3
- 20.12%
- Median
- 8.91%
- Q1
- 2.62%
- Min
- -23.39%
SHEL’s Net Profit Margin of 5.00% is aligned with the median group of its peers in the Oil, Gas & Consumable Fuels industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
AZN
20.04%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
AZN’s Operating Profit Margin of 20.04% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
SHEL
9.81%
Oil, Gas & Consumable Fuels Industry
- Max
- 64.72%
- Q3
- 31.93%
- Median
- 19.14%
- Q1
- 5.67%
- Min
- -27.31%
SHEL’s Operating Profit Margin of 9.81% is around the midpoint for the Oil, Gas & Consumable Fuels industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | AZN | SHEL |
|---|---|---|
| Return on Equity (TTM) | 19.84% | 7.40% |
| Return on Assets (TTM) | 7.76% | 3.45% |
| Net Profit Margin (TTM) | 14.68% | 5.00% |
| Operating Profit Margin (TTM) | 20.04% | 9.81% |
| Gross Profit Margin (TTM) | 82.07% | 24.92% |
Financial Strength
Current Ratio (MRQ)
AZN
0.86
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
AZN’s Current Ratio of 0.86 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
SHEL
1.32
Oil, Gas & Consumable Fuels Industry
- Max
- 2.76
- Q3
- 1.64
- Median
- 1.22
- Q1
- 0.84
- Min
- 0.22
SHEL’s Current Ratio of 1.32 aligns with the median group of the Oil, Gas & Consumable Fuels industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
AZN
0.73
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
AZN’s Debt-to-Equity Ratio of 0.73 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
SHEL
0.43
Oil, Gas & Consumable Fuels Industry
- Max
- 2.24
- Q3
- 1.06
- Median
- 0.60
- Q1
- 0.24
- Min
- 0.00
SHEL’s Debt-to-Equity Ratio of 0.43 is typical for the Oil, Gas & Consumable Fuels industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
AZN
9.51
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
AZN’s Interest Coverage Ratio of 9.51 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
SHEL
-16.99
Oil, Gas & Consumable Fuels Industry
- Max
- 54.03
- Q3
- 23.32
- Median
- 7.46
- Q1
- 2.57
- Min
- -19.25
SHEL has a negative Interest Coverage Ratio of -16.99. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | AZN | SHEL |
|---|---|---|
| Current Ratio (MRQ) | 0.86 | 1.32 |
| Quick Ratio (MRQ) | 0.67 | 1.08 |
| Debt-to-Equity Ratio (MRQ) | 0.73 | 0.43 |
| Interest Coverage Ratio (TTM) | 9.51 | -16.99 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AZN
2.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
AZN’s Dividend Yield of 2.00% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
SHEL
4.11%
Oil, Gas & Consumable Fuels Industry
- Max
- 13.98%
- Q3
- 7.41%
- Median
- 4.36%
- Q1
- 2.84%
- Min
- 0.00%
SHEL’s Dividend Yield of 4.11% is consistent with its peers in the Oil, Gas & Consumable Fuels industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
AZN
59.51%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
AZN’s Dividend Payout Ratio of 59.51% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
SHEL
63.10%
Oil, Gas & Consumable Fuels Industry
- Max
- 180.73%
- Q3
- 92.90%
- Median
- 63.90%
- Q1
- 27.41%
- Min
- 0.00%
SHEL’s Dividend Payout Ratio of 63.10% is within the typical range for the Oil, Gas & Consumable Fuels industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | AZN | SHEL |
|---|---|---|
| Dividend Yield (TTM) | 2.00% | 4.11% |
| Dividend Payout Ratio (TTM) | 59.51% | 63.10% |
Valuation
Price-to-Earnings Ratio (TTM)
AZN
29.72
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
A P/E Ratio of 29.72 places AZN in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
SHEL
15.36
Oil, Gas & Consumable Fuels Industry
- Max
- 41.71
- Q3
- 21.35
- Median
- 12.26
- Q1
- 7.77
- Min
- 0.00
SHEL’s P/E Ratio of 15.36 is within the middle range for the Oil, Gas & Consumable Fuels industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
AZN
4.36
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
AZN’s P/S Ratio of 4.36 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SHEL
0.77
Oil, Gas & Consumable Fuels Industry
- Max
- 5.87
- Q3
- 2.89
- Median
- 1.29
- Q1
- 0.54
- Min
- 0.00
SHEL’s P/S Ratio of 0.77 aligns with the market consensus for the Oil, Gas & Consumable Fuels industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
AZN
4.74
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
AZN’s P/B Ratio of 4.74 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SHEL
1.28
Oil, Gas & Consumable Fuels Industry
- Max
- 3.83
- Q3
- 2.12
- Median
- 1.34
- Q1
- 0.91
- Min
- 0.34
SHEL’s P/B Ratio of 1.28 is within the conventional range for the Oil, Gas & Consumable Fuels industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | AZN | SHEL |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 29.72 | 15.36 |
| Price-to-Sales Ratio (TTM) | 4.36 | 0.77 |
| Price-to-Book Ratio (MRQ) | 4.74 | 1.28 |
| Price-to-Free Cash Flow Ratio (TTM) | 30.13 | 7.27 |